Cooper Companies Inc (COO) reported financial results for the second quarter of fiscal 2026 that surpassed analyst expectations. The company achieved earnings per share (EPS) of $1.21, exceeding the consensus estimate of $1.11 by $0.10. Revenue for the quarter matched expectations at $1.1 billion.
The results reflect the operational strength of Cooper Companies, which operates in the health care sector with a focus on medical devices. The firm is headquartered in San Ramon, California, and employs approximately 16,000 individuals. It operates through two primary business units: CooperVision, which is engaged in the contact lens industry, and CooperSurgical, which focuses on fertility and women's health care products and services.
CooperVision’s offerings include a range of contact lenses, such as MyDay daily disposables and Biofinity. Meanwhile, CooperSurgical provides various medical devices and fertility solutions, including cryostorage services and surgical products.
The company will host an earnings conference call to discuss these results in further detail. Investors are encouraged to review the full earnings release and management commentary for comprehensive insights into performance and future outlook. Upcoming earnings are scheduled for August 25, 2026, with EPS and revenue estimates both set at $1.20 and $1.1 billion, respectively.